MDS1/EVI1, located on chromosome 3 band q26, encodes a zinc-finger DNA-binding transcription activator not detected in normal hematopoietic cells but expressed in several normal tissues. MDS1/EVI1 is inappropriately activated in myeloid leukemias following chromosomal rearrangements involving band 3q26. The rearrangements lead either to gene truncation, and to expression of the transcription repressor EVI1, as seen in the t(3;3)(q21;q26) and inv(3)(q21q26), or to gene fusion, as seen in the t(3;21)(q26;q22) which results in the fusion protein AML1/MDS1/EVI1. This fusion protein contains the DNA-binding domain of the transcription factor AML1 fused in-frame to the entire MDS1/EVI1 with the exclusion of its first 12 amino acids. In this report, we have analyzed the response of the hematopoietic precursor cell line 32Dcl3, expressing either the normal protein MDS1/EVI1 or the fusion protein AML1/MDS1/EVI1, to factors that control cell differentiation or cell replication. The 32Dcl3 cells are IL-3-dependent for growth and they differentiate into granulocytes when exposed to G-CSF. They are growth-inhibited by TGF-␤1. We show that whereas the expression of MDS1/EVI1 has no effect on granulocytic differentiation induced by G-CSF, expression of AML1/MDS1/EVI1 blocks differentiation resulting in cell death. This effect is similar to that previously described by others for 32Dcl3 cells that express transgenic Evi1. Furthermore, we show that whereas the expression of the fusion protein AML1/MDS1/EVI1 completely abrogates the growth-inhibitory effect of TGF-␤1 and allows 32Dcl3 cells to proliferate, expression of the normal protein MDS1/EVI1 has the opposite effect, and it strengthens the response of cells to the growth-inhibitory effect of TGF-␤1. By using the yeast two-hybrid system, we also show that EVI1 (contained in its entirety in MDS1/EVI1 and AML1/MDS1/EVI1) physically interacts with SMAD3, which is an intracellular mediator of TGF-␤1 signaling. Finally, we have correlated the response of the cells to G-CSF or TGF-␤1 with the ability of the normal and fusion proteins to activate or repress promoters which they can directly regulate by binding to the promoter site. We propose that mutations of MDS1/EVI1 either by gene truncation resulting in the transcription repressor EVI1 or by gene fusion to AML1 lead to an altered cellular response to growth and differentiation factors that could result in leukemic transformation. The different response of myeloid cells ectopically expressing the normal or the fusion protein to G-CSF and TGF-␤1 could depend on the different transactivation properties of these proteins resulting in divergent expression of downstream genes regulated by the two proteins.
Introduction
The MDS1/EVI1 gene, located at chromosome band 3q26, is expressed in several normal tissues. 1, 2 This gene is inappropriately activated in human myeloid leukemias associated with 3q26 abnormalities. [1] [2] [3] [4] The MDS1/EVI1 gene encodes a zinc- finger transcription factor that contains the entire EVI1 sequence, and in addition, a unique 5′ extension known as the PR domain (PRDI-BF1-RIZ1 homologous region) which is highly conserved across species. 1, 5 The PR domain was first defined by homology between the PRDI-BF1 transcription factor and the retinoblastoma-binding protein, RIZ1. It consists of three blocks of about 12 highly conserved amino acid residues separated by stretches of about 30 less conserved amino acids. 1, 5 MDS1/EVI1 shares an overall homology with the C. elegans protein Egl 43 that includes the PR domain at the Nterminus and the two zinc-finger domains. 4, 6 The MDS1/EVI1 locus is targeted by several chromosomal rearrangements associated with leukemia. The most frequent rearrangements are the translocation (3;3)(q21;q26) and the paracentric inversion inv(3)(q21q26), both of which lead to the expression of EVI1, a protein which lacks the N-terminal PR domain. 4, [7] [8] [9] [10] MDS1/EVI1 is also activated by reciprocal translocations of chromosome 3, such as in t(3;21)(q26;q22). 1, 2, [11] [12] [13] This translocation is rarely seen in de novo leukemias, and is usually associated with chronic myelogenous leukemia (CML) and with therapy-related myelodysplastic syndrome and acute myelogenous leukemia (t-MDS/AML). [14] [15] [16] [17] The t(3;21) (q26,q22) fuses the AML1 gene (also known as CBFA2), located on chromosome 21 band q22, to MDS1/EVI1, and results in the fusion transcript AML1/MDS1/EVI1.
2 AML1 encodes the DNA-binding subunit of the transcription factor CBF. 18, 19 The AML1/MDS1/EVI1 fusion gene encodes a protein containing the DNA-binding domain contributed by AML1 and almost the entire MDS1/EVI1. 2 The PR domain is completely maintained in the fusion protein AML1/ MDS1/EVI1. This chimeric transcription factor can potentially bind to the DNA target sites of both AML1 and EVI1, and we have previously shown that, in contrast to AML1 which is an activator, AML1/MDS1/EVI1 binds to AML1 target sites and inhibits transactivation by AML1. 20 MDS1/EVI1 as well as EVI1 are nuclear proteins (Refs 21-25 and RS, unpublished results) with two zinc-finger DNAbinding domains that recognize a DNA sequence with a central AGATA motif. 3, [23] [24] [25] The two proteins have different properties. EVI1 is a transcriptional repressor 26 associated with myeloid leukemias, 7 and is overexpressed in a limited number of AML patients with t(3;3) or inv (3) . 3 MDS1/EVI1, in contrast, is a strong transcriptional activator, identified so far only in normal tissues. 3, 4 Ectopic expression of EVI1 in the 32Dcl3 myeloid cell line and in murine bone marrow blocks granulocytic or erythroid differentiation in response to growth factors. 26, 27 On this basis it was hypothesized that EVI1 interferes with normal hematopoietic differentiation. Recently it was reported that EVI1 expressed in Mv1Lu cells antagonizes the growth inhibitory effect of TGF-␤1 and suppresses the activation of a TGF-␤1-responsive promoter. It was proposed that the effect of EVI1 on TGF-␤1 signaling is mediated by its physical association with SMAD3. 28 In this study we have examined the response of the hemato-MDS1/EVI1 enhances TGF-␤1 signaling R Sood et al 349 poietic progenitor cell line 32Dcl3 expressing the normal protein MDS1/EVI1 or the fusion protein AML1/MDS1/EVI1, generated in t (3;21) , to the growth factors G-CSF and TGF-␤1. 32Dcl3 cells depend on IL-3 for growth in culture, and differentiate into granulocytes in response to stimulation with G-CSF. We show that whereas cells expressing the fusion protein do not differentiate but die when switched from IL-3 to G-CSF, the expression of the normal protein MDS1/EVI1 has no effect on their ability to differentiate. We also demonstrate that the fusion protein AML1/MDS1/EVI1 completely abrogates the growth inhibitory effect of TGF-␤1 on 32Dcl3 cells. In contrast, the normal protein MDS1/EVI1 enhances the ability of TGF-␤1 to repress cellular growth compared to the control 32Dcl3 cells. We propose that alterations of MDS1/EVI1 either by gene truncation or by gene fusion lead to an aberrant response of hematopoietic precursor cells to growth factors regulating proliferation and differentiation, leading to leukemic transformation.
Materials and methods

Plasmids used
The cDNAs encoding EVI1, MDS1/EVI1, and full length AML1/MDS1/EVI1 have been previously described. [1] [2] [3] Refer to Figure 1 for a diagrammatic representation. The cDNAs were cloned into the unique EcoRI site of the retroviral vector SR␣MSVtkneo (gift of Dr Owen N Witte, UCLA, CA, USA). 29 The reporter gene construct pTAK150-CAT, used in the reporter gene assays, expresses chloramphenicol acetyl transferase (CAT) under the control of a promoter/enhancer element with AGATA binding sites, and has been previously described. 26 For normalization of the efficiency of transient transfections, pCH110 (Pharmacia, Piscataway, NJ, USA) that expresses ␤-galactosidase or pRL-TK (Promega, Madison, WI, USA) that expresses Renilla luciferase were used. For TGF-␤1 responsiveness, we used plasmid p3TP-Lux containing the plasminogen-activator-1 (PAI-1) promoter. 30 
Cell culture
Conditions for growth, infection, and selection of 32Dcl3 cells have been reported. 31, 32 To avoid clonal variation due to the integration site of the retrovirus, we used small pools of infected clones in our assays, and infections were repeated at 
Cytochemistry
To analyze their morphology, cells grown in G-CSF were harvested on days 7, 10 and 14 after switching from IL-3 to G-CSF-containing medium. Cells were centrifuged on to glass slides in a cytospin centrifuge and stained with WrightGiemsa stain (Sigma, St Louis, MO, USA) for a microscopic examination of differentiation. Cytospin preparations made on day 7 were also stained for myeloperoxidase using the leukocyte staining kit (Sigma) according to the manufacturer's directions.
32Dcl3 proliferation assay
For colonogenic assays, 2 × 10 3 or 5 × 10 3 cells/plate were plated in IMDM medium containing 0.9% methylcellulose, 15% FBS, 2.5 mm l-glutamine, and 2.5 ng/ml IL-3. TGF-␤1 was added at a concentration of 3 ng/ml to one set of plates to monitor its effect on growth suppression. The colonies were examined after 7 to 10 days of culture. For liquid proliferation assays, cells were plated at a concentration of 0.5 × 10 5 /ml in a 200 l volume in 96-well plates in IMDM with 10% FBS and 2.5 ng/ml IL-3 in the presence or absence of 0.3 to 30 ng/ml of TGF-␤1. After 48 h of culture, cells were pulsed for 18 h with 1 Ci per well of 3 H-thymidine. The cells were collected on a 96-well filter dish, and the incorporated radioactivity was determined by liquid scintillation counting.
Northern and Western blot analysis, and electrophoretic mobility shift assays (EMSA)
Northern and Western blot analyses were performed using standard procedures. Briefly, 25 g of total RNA from each pool of 32Dcl3 clones was fractionated by electrophoresis on a 1% formaldehyde agarose gel, transferred to nylon membrane, and sequentially probed with PCR amplified fragments of a 3′ region of human EVI1 cDNA and murine G6pd cDNA. For Western blot analysis, total cellular extracts were fractionated on 7% SDS polyacrylamide gels, transferred on to PVDF membranes, immunostained with anti-EVI1 antiserum (gift of Dr JN Ihle), and detected by chemiluminescence with ECL reagents (Amersham, Arlington Heights, IL, USA) according to the manufacturer's directions. The conditions and the probe used for EMSA assays have been described previously. 3 
Reporter gene assays
The plasmids used to express EVI1, MDS1/EVI1, and AML1/MDS1/EVI1 in transient transfections have been previously described. 3, 20 For CAT assays, NIH-3T3 cells were cotransfected with the calcium phosphate co-precipitation method 33 with pTAK150-CAT, pCH110, and the appropriate cDNA clone. Cells were harvested 46 h post-transfection, and cellular extracts were prepared by disruption of the cell membrane with four cycles of cell freezing and thawing. The samples were immediately centrifuged, and the level of CAT enzyme in the supernatants was determined using the CAT ELISA kit (Boehringer Mannheim, Indianapolis, IN, USA) following the manufacturer's directions. The efficiency of transfections was normalized with the levels of ␤-galactosidase enzyme in the supernatants. All measurements were done in duplicate, and the assays were repeated at least twice. For luciferase assays, the Dual Luciferase Reporter Assay System (Promega) was used. NIH-3T3 cells were transiently co-transfected with p3TP-Lux, pRL-TK, and the appropriate cDNA clones. Cells were treated with TGF-␤1 for 24 h. Measurement of luciferase activity was performed according to the manufacturer's directions. The efficiency of transfections was normalized with the levels of Renilla luciferase activity.
Yeast 2-hybrid interaction assay
The Matchmaker two-hybrid system (Clontech, Palo Alto, CA, USA) was used for the in vivo interaction assay. The human SMAD3 c-DNA was cloned in frame with the Gal-4 DNA binding domain into plasmid pGBT9, resulting in plasmid pGBT9-SMAD3. The full length EVI1 c-DNA was cloned inframe with the activating domain into plasmid pGAD424 resulting in plasmid pGAD424-EVI1. Selection of yeast colonies carrying both plasmids, and ␤-galactosidase assays were done according to the manufacturer's directions.
Results
AML1/MDS1/EVI1, but not MDS1/EVI1, inhibits granulocytic differentiation of 32Dcl3 cells
32Dcl3 is a murine hematopoietic precursor cell line that is IL-3-dependent for growth, and differentiates into granulocytes when IL-3 is replaced by G-CSF. Because of this ability to differentiate, the 32Dcl3 cells have often been used as a model system to study the effect of ectopically expressed oncoproteins on granulocytic differentiation. The effect of EVI1 on these cells has been well described: cells that express EVI1 as a transgene grow in IL-3, but consistently die 2 to 4 days after IL-3 is replaced by G-CSF. 27 We infected 32Dcl3 cells with either the vector alone or with a recombinant retrovirus expressing either MDS1/EVI1 or AML1/MDS1/EVI1. Cells infected with retrovirus expressing EVI1 and SR␣-32Dcl3 cells were used as controls. Figure 1 shows a diagrammatic representation of the cDNAs used in this study. In order to avoid clonal variability, we used small pools of clonal populations of cells. Naive and infected 32Dcl3 cells maintained a requirement for IL-3 for growth and viability. Figure 2 shows the viability of naive and infected 32Dcl3 cells upon withdrawal of IL-3 and addition of G-CSF. As expected, naive and SR␣-32Dcl3 cells show an initial decline in viability after 2-3 days of culture in the presence of G-CSF. The cells grew briefly for 3-4 days, and by day 7 they visibly underwent differentiation. In contrast, cells expressing AML1/MDS1/EVI1 showed a sharp decline (70-80%) in viability, and by day 3-4 in G-CSF, most of the cells appeared dead as determined by trypan blue staining. These results are similar to what has been previously reported for EVI1. However, MDS1/EVI1 cells consistently differentiated normally, and their response to G-CSF was very similar to that observed for the naive cells. Figure 3 shows the results of the Northern blot analysis indicating that all the transgenes were expressed.
It was recently reported that 32Dcl3 cells constitutively express Evi1 because of a retroviral insertion and rearrangement of the Evi1 locus that activates the gene. 34 To determine the level of endogenous Evi1 expression in naive 32Dcl3 cells and to compare it to that of the transgenes, we performed a Northern blot analysis with a murine Evi1 cDNA probe. The level of endogenous gene expression was undetectable, and the only hybridization we could identify was cross-hybridization of the murine probe to the ectopically expressed human cDNAs (data not shown). We did however confirm the expression of endogenous Evi1 by RT-PCR with primers spe- cific for the mouse sequence (data not shown). We concluded that the level of endogenous gene expression in the 32Dcl3 parental clone that we used is much lower than the expression of the transgenes. We should point out that other laboratories have also not detected expression of the endogenous gene by Northern and Western blot analysis. 27 We examined the morphology of cells in G-CSF to assess their maturation from blasts to progressive stages of differentiation as promyelocytes, myelocytes, mature bands, and neutrophils by Wright-Giemsa staining. Figure 4a shows the Wright-Giemsa staining preparations of cells maintained in IL-3 and in G-CSF. As expected, after 10 days in G-CSF, WrightGiemsa staining identified a number of naive and SR␣-32Dcl3 cells with indented nuclei, and several mature neutrophils with segmented nuclei, providing evidence that these cells undergo differentiation in response to G-CSF. We confirmed that the majority of 32Dcl3 cells expressing EVI1 were dead with the exception of very rare undifferentiated cells. Similarly, the majority of the cells expressing AML1/MDS1/EVI1 were also dead. Both in EVI1 and in AML1/MDS1/EVI1 cells no mature neutrophils were observed. In contrast, cells expressing MDS1/EVI1 were clearly differentiating, and mature band cells and neutrophils were readily identified after 10 days of culture in G-CSF (Figure 4a ). To confirm that MDS1/EVI1 cells differentiated correctly, we examined the induction of myeloperoxidase (Mpo) in cells after culturing in medium containing G-CSF for 7 days. Mpo is an early marker that appears at the promyelocytic stage. Mpo staining results showed that naive, SR␣, and MDS1/EVI1-32Dcl3 cells developed brown-black cytoplasmic granules by day 7, indicating that the cells were Mpo-positive (Figure 4b ). Results for AML1/MDS1/EVI1-32Dcl3 cells are also shown (Figure 4b ). These results are consistent with the morphology of the cells observed with the Wright-Giemsa stain, and confirm that, in contrast to AML1/MDS1/EVI1 and EVI1, MDS1/EVI1 has no inhibitory effect on the granulocytic differentiation of 32Dcl3 cells in response to G-CSF.
AML1/MDS1/EVI1, but not MDS1/EVI1, inhibits TGF-␤1 signaling
Several investigators have previously shown that TGF-␤1 is a very potent inhibitor of hematopoietic progenitor cell proliferation, and that this factor may be critical in maintaining an appropriate balance between renewal and commitment/ differentiation of early hematopoietic progenitors in vivo. 35 Recently, it was reported that EVI1 antagonizes the proliferation-inhibitory effect of TGF-␤1 by binding to the intracellular mediator SMAD3 through the proximal zinc-finger domain, and suppressing the DNA-binding activity of the SMAD3/SMAD4 complex. 28 To confirm that the interaction between EVI1 and SMAD3 occurs, we cloned the entire cDNA of EVI1 (which is also contained in MDS1/EVI1 and in AML1/MDS1/EVI1, Figure 1 ), in the yeast plasmid pGAD424 as in-frame fusion with the activation domain of the yeast protein Gal-4. We used this plasmid to co-transform yeast cells with pGBT9-SMAD3, in which the SMAD3 cDNA was cloned in-frame with the DNA-binding domain of Gal-4. In the yeast cell, if physical interaction between EVI1 and SMAD3 occurs, the interaction will result in the assembly of a functional Gal-4 transcription factor that can then activate the ␤-galactosidase gene. Beta-galactosidase assays were performed on colony lifts of co-transformed yeast cells grown on selection plates. The results of this assay, summarized in Table 1 , indicate that in yeast cells such an interaction exists. Yeast colonies carrying pGBT9 or pGAD424 alone or in combination with either pGAD424-EVI1 or pGBT9-SMAD3 did not induce ␤-galactosidase expression, whereas yeast colonies carrying both pGAD424-EVI1 and pGBT9-SMAD3 induced the expression of the ␤-galactosidase marker (Table 1) . The effect of TGF-␤1 on the proliferative response of naive and infected 32Dcl3 cells was examined in liquid culture as a function of 3 H-thymidine incorporation. The assays were done in triplicate, and the results are shown in Figure 5 . It was previously reported that 32Dcl3 cells are TGF-␤1-responsive, and that their growth is repressed by about 50% in the presence of TGF-␤1. 36 Our results confirm this report, and we observed a decrease in 3 H-thymidine incorporation, indicative of growth inhibition, in naive 32Dcl3 cells in the presence of TGF-␤1, ( Figure 5 , black circles). Our results indicate that 32Dcl3 cells that express EVI1 ( Figure 5 , empty squares) have acquired more resistance to the growth-inhibitory effect of TGF-␤1 over a large range of concentration (10-1000 pm), in agreement to what was recently reported by others for the Mv1Lu cell line. 28 The largest incorporation of 3 H-thymidine was observed with 32Dcl3 cells that expressed the fusion protein AML1/MDS1/EVI1 ( Figure 5 , empty circles), indicating that the fusion protein produced by the t(3;21) completely represses the growth-inhibitory effect of TGF-␤1 even at a very high concentration (1 nm). The normal gene MDS1/EVI1 also had a striking effect in modulating the cellular growth in response to TGF-␤1. As shown in Figure 5 (black squares), expression of MDS1/EVI1 enhanced the growth-inhibitory effects of TGF-␤1, and resulted in lower 3 H-thymidine incorporation than for the naive cells. It should be noted that the normal protein MDS1/EVI1 is almost completely conserved in the fusion protein AML1/MDS1/EVI1 aside from the first 12 amino acids of MDS1/EVI1 which are lost as a result of the chromosomal translocation, and that the major difference between the two proteins is the contribution given by AML1 in the fusion protein.
To confirm the results obtained with cell cultures grown in liquid medium, we repeated the assays using semisolid medium. When grown in methylcellulose, the 32Dcl3 cells form distinct colonies in the presence of IL-3. It was previously shown that the growth of the colonies is repressed by addition of TGF-␤1 to the semisolid medium. 36 To determine the effect of the normal and altered MDS1/EVI1 proteins on colony formation and colony growth, we plated equal numbers of infected 32Dcl3 cells in methylcellulose in the presence of IL-3, and with or without TGF-␤1. The results of the assay are shown in Figure 6 . As expected, 32Dcl3 cells infected with the empty retroviral vector are growth inhibited and form smaller colonies in methylcellulose upon addition of TGF-␤1 ( Figure 6 , left column). 32Dcl3 cells that express EVI1 form colonies that grow very well in IL-3, and addition of TGF-␤1 reduces, but does not block their growth (Figure 6 , center-left column). However, 32Dcl3 cells that express the fusion protein AML1/MDS1/EVI1 are completely non-responding to TGF-␤1, and the size of the colonies produced in the presence or in the absence of TGF-␤1 is the same (Figure 6 , centerright column). The MDS1/EVI1-32Dcl3 cells did not grow in 
Figure 6
AML1/MDS1/EVI1 abrogates growth-inhibition induced by TGF-␤1 in semisolid medium. Identical number of cells were plated in methylcellulose, in the absence and in the presence of TGF-␤1 as described in Materials and methods. Top: colonies of similar size were observed in plates containing SR␣-32Dcl3, EVI1-32Dcl3 and AML1/MDS1/EVI1-32Dcl3 (indicated as A/M/E) cells growing in IL-3 alone. Bottom: after addition of TGF-␤1, SR␣-32Dcl3 cells showed very small colonies. EVI1-32Dcl3 cells were partially growth-inhibited. AML1/MDS1/EVI1-32Dcl3 cells produced colonies of the same size as those observed in IL-3 alone. MDS1/EVI1-32Dcl3 cells did not grow in IL-3 ± TGF-␤1. methylcellulose even in the absence of TGF-␤1 ( Figure 6 , right column). This effect could be a specific phenotype of cells expressing MDS1/EVI1. We are currently investigating this property of MDS1/EVI1-32Dcl3 cells.
MDS1/EVI1 and AML1/MDS1/EVI1 have opposite effect as transcription regulators
We have shown in this report that 32Dcl3 cells that express the fusion protein AML1/MDS1/EVI1 have lost the ability to respond correctly to TGF-␤1 and G-CSF in contrast to cells that express MDS1/EVI1. To determine whether these opposite effects of the two proteins are related to their properties as transcription regulators, we performed reporter gene assays with pTAK150CAT that contains a genomic promoter with AGATA repeats. We have previously shown that MDS1/EVI1 is a strong transcription activator of this promoter. 3 We have used the same system to determine the effects of AML1/MDS1/EVI1 on transcription regulation. The results of the assays, shown in Figure 7a , indicate that whereas MDS1/EVI1 is a strong activator (Figure 7a, lane 3) , AML1/MDS1/EVI1 has almost completely lost the ability to activate the promoter (Figure 7a, lane 2) . Indeed, we consistently observed a reduction of about 80% in the activation with AML1/MDS1/EVI1 as compared to that with MDS1/EVI1. We determined that AML1/MDS1/EVI1 was able to interfere with and repress the transactivation by MDS1/EVI1 (Figure 7b ) and that equimolar amounts of both plasmids produced about 50% reduction in transcription activity of MDS1/EVI1. It should be noted that AML1/MDS1/EVI1 is a bifunctional repressor that also inhibits promoters regulated by AML1 as we previously reported. 20 By electrophoretic mobility shift assays (EMSA), we confirmed that the fusion protein recognizes and binds to a DNA target containing AGATA sequences (Figure 8 , lane 9) as well as MDS1/EVI1 and EVI1, tested as controls (Figure 8, lanes 3  and 7) . The probe-protein complex is disrupted by the addition of an excess of unlabelled competitor DNA (Figure 8 , lane 10), indicating that the protein-DNA binding is specific. Additional bands due to specific or non-specific DNA binding were also observed (Figure 8, lanes 1, 2, 5 and 6 ).
MDS1/EVI1 and AML1/MDS1/EVI1 repress a TGF-␤1-responding promoter
We examined the effect of the normal and fusion protein on a promoter responding to TGF-␤1. In these assays, we used the plasmid p3TP-Lux, that has been previously used for analysis of gene expression induced by TGF-␤1. 30, 37 The p3TP promoter was empirically designed to have maximal responsiveness to TGF-␤1. The promoter contains a 31 bp region from the collagenase promoter that has binding sites for the transcription factor AP1. This region was concatimerized and cloned upstream of about 0.4 kb of the PAI-1 promoter followed by the adenovirus E4 promoter. 38 We co-transfected NIH-3T3 cells in the presence or absence of TGF-␤1 with p3TP-Lux and a plasmid encoding either MDS1/EVI1, or the fusion protein MDS1/AML1/EVI1, or EVI1, used as control. The results, shown in Figure 9 , indicate that all the three proteins repress the transcription activation of the promoter approximately at the same level in the presence of TGF-␤1 ( Figure 9, lanes 4, 6 and 8) . However, we observed that the expression of these proteins considerably reduced the activity of the promoter also in the absence of TGF-␤1 ( Figure 9 , lanes 3, 5 and 7), suggesting that these proteins affect the activity of the promoter independently of TGF-␤1. It is important to note that in contrast to the pTAK150CAT promoter used in the assays described earlier, the p3TP-Lux promoter contains no binding site for any one of the three proteins, and therefore their effect on the promoter is indirect. Given the complexity of the artificial promoter p3TP-Lux that we used, it is likely that the response of the promoter is affected by several transcription factors which are active in the cells. The mechanisms by which the three proteins affect the promoter in the absence of TGF-␤1 is currently under study.
Discussion
An appropriate response to growth and differentiation factors is critical for the regulation of self-renewal, commitment, maturation and survival of a hematopoietic cell. In this report, we have investigated the effects of the expression of the normal protein MDS1/EVI1 and the fusion protein AML1/MDS1/EVI1, generated in the t(3;21), on proliferation and differentiation of the hematopoietic precursor cell line 32Dcl3 in response to G-CSF and TGF-␤1. We have determined that MDS1/EVI1 has no noticeable effect on granulo-
Figure 9
The normal and fusion protein indirectly repress a TGF-␤1-responsive promoter. NIH-3T3 cells were co-transfected with pRL-TK, p3TPLux and plasmids expressing the normal gene MDS1/EVI1 (indicated as M/E) or the fusion gene AML1/MDS1/EVI1 (indicated as A/M/E). Reporter gene activity readings were normalized to relative expression of Renilla luciferase and plotted as shown. In co-transfections with the empty vector SR␣MSVtkneo, the addition of TGF-␤1 increased the expression of the reporter gene by about eight-fold (lanes 1 and 2) . In the absence of TGF-␤1 (black boxes), co-transfection with any one of the three plasmids analyzed (lanes 3, 5, and 7) decreased the level of promoter activation about two-to five-fold compared to the control (lane 1). Activation of the reporter gene by any one of the three proteins in the presence of TGF-␤1 (lanes 4, 6 and 8) was similar, and corresponded to about 8-10% of that observed for the vector alone.
cytic differentiation induced by G-CSF, and that the cells mature with a pattern identical to that observed for the control cells. In contrast, we found that the fusion protein AML1/MDS1/EVI1 blocks the response of the cells to this cytokine and results in cell death. This response is similar to that observed for EVI1 and for AML1/EVI1, a variant form of AML1/MDS1/EVI1 that results from a t(3;21) with the breakpoint in a different intron of the AML1 gene. 39 We also show that 32Dcl3 cells that express either the normal or the fusion protein as a transgene have opposite response to the growthinhibitory effect of TGF-␤1. Whereas expression of AML1/MDS1/EVI1 completely relieves the cells from growthinhibition in response to TGF-␤1 both in liquid culture and in semisolid medium, MDS1/EVI1 works in concert with TGF-␤1, and in comparison to the normal 32Dcl3 cells, cells expressing MDS1/EVI1 show a higher growth repression in response to TGF-␤1. In our assays with TGF-␤1, EVI1 appears to produce an intermediate effect between that of AML1/MDS1/EVI1 and that of the normal cells in liquid and in semisolid medium. EVI1 cells grew better than those of naive cells but more slowly than the AML1/MDS1/EVI1 cells.
It has been recently reported that EVI1 represses TGF-␤1 signaling and antagonizes its growth-inhibitory effect. 28 It was suggested that two separate regions of EVI1 are responsible for this repression. One of the two regions is the proximal zinc-finger domain, and Kurokawa et al 28 showed that EVI1 interacts with SMAD3 through this domain and prevents the binding of the SMAD3/SMAD4 complex to its DNA target sites. Although the normal and the fusion protein both contain this domain that in EVI1 interacts with SMAD3, our data show that the two proteins have a completely opposite effect on TGF-␤1-responsiveness of 32Dcl3 cells. Therefore, it is likely that the mechanism by which AML1/MDS1/EVI1 abrogates the growth inhibitory effect of TGF-␤1 and MDS1/EVI1 strengthens its effect is much more complex than that proposed by Kurokawa et al. Our assays show that MDS1/EVI1 enhances the growthinhibitory effect of TGF-␤1, and we would like to propose that one of the functions of MDS1/EVI1 could be to control and to limit cellular replication, perhaps in conjunction with factors such as TGF-␤1 which are involved in growth control. Further, we would like to propose that mutations such as truncation or protein fusion that change the structure or the biochemical properties of the N-terminus of MDS1/EVI1 also modify the ability of MDS1/EVI1 to control cellular growth. The N-terminus of MDS1/EVI1 consists essentially of the PR domain. This region is related to the SET domain, and it was suggested that the PR domain has an inhibiting role in tumorigenesis. 40 It was recently shown that the expression of RIZ1 protein which contains the PR domain, but not of its shorter form RIZ2 which lacks the PR domain, is decreased or lost in breast cancer. 41 Similarly, the forced expression of BLIMP1, another protein containing the PR domain, causes differentiation or apoptosis depending on the cell type. 42, 43 Thus, it is not unlikely that the PR domain could be involved in pathways controlling cell proliferation or cell differentiation in response to growth factors. Although the fusion protein AML1/MDS1/EVI1 also contains the PR domain, it is possible that the AML1 sequence fused upstream of the PR domain may cause an alteration in the structure of the folded protein disrupting the normal function of the PR domain. We have previously assigned a transactivation function to the PR domain, 3 and this transactivation ability is lost in EVI1 and in AML1/MDS1/EVI1. It is also important to note that AML1/MDS1/EVI1 is a bifunctional repressor that inhibits promoters regulated by AML1 20 and could have functions unrelated to MDS1/EVI1 affecting its response to growth factors.
In conclusion, we have shown that two very similar proteins which differ essentially in their N-terminus, have opposite effects to growth factors. These proteins are MDS1/EVI1 and AML1/MDS1/EVI1, product of the t(3;21). It is tempting to speculate that the t(3;21) resulting in the expression of the fusion protein abrogates response to TGF-␤1 signaling and induces continuous proliferation of the altered hematopoietic cells.
